Article thumbnail

A Wnt1 regulated Frizzled-1/β-Catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: Therapeutical relevance for neuron survival and neuroprotection

By Francesca L'Episcopo, Maria F Serapide, Cataldo Tirolo, Nunzio Testa, Salvatore Caniglia, Maria C Morale, Stefano Pluchino and Bianca Marchetti
Topics: Research Article
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2009). A: α-Synuclein contributes to GSK-3β-catalyzed Tau phosphorylation in Parkinson’s disease models. Faseb J
  2. (2005). Abbracchio MP: To be or not to be (inflammed) is that the question in anti-inflammatory drug therapy of neurodegenerative diseases? Trends in Pharmacological Sci
  3. (1999). Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4-phenylpyridiniumand 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-cultures.
  4. (2000). AP: Wnt-1 dependent activation of the survival factor NF-kappaB in PC12 cells.
  5. (2008). Barres BA: A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function.
  6. (2000). Basic fibroblast growth factor (bFGF) acts on both neurons and glia to mediate the neurotrophic effects of astrocytes on LHRH neurons in culture. Synapse
  7. (2000). Basic fibroblast growth factor priming increases the responsiveness of immortalized hypothalamic luteinizing hormone releasing hormone neurones to neurotrophic factors.
  8. (1997). Beta-catenin is a target for the ubiquitin-proteasome pathway.
  9. (2004). Bilirubin protects astrocytes from its own toxicity inducing up-regulation and translocation of multigrug resistance-associated protein 1 (Mrp 1). Proc Natl Acad Sci USA
  10. (2007). Cellular demise and inflammatory microglial activation during β-amyloid toxicity are governed by WNT1 and canonical signaling pathways. Cell Signal
  11. (2010). Cheng YG: Dishevelled:The hub of Wnt signalling. Cell Signal
  12. (2000). CM: Regulation and localization of tyrosine 216 phosphorylation of glycogen synthase kinase-3β in cellular and animal models of neuronal degeneration. Proc Natl Acad Sci USA
  13. (1994). Commissiong JW: Mesencephalic type 1 astrocytes rescue dopaminergic neurons from death induced by serum deprivation.
  14. (1997). Cross-talk signals in the CNS: Role of neurotrophic and hormonal factors, adhesion molecules and intercellular signaling agents in luteinizing hormone-releasing hormone (LHRH) neuron-astroglia interactive network. Trends in Biosci
  15. (2008). DA: Msx2 exerts bone anabolism via canonical Wnt signaling.
  16. (2001). DJ: Insights into Wnt binding and signalling from the structures of two Frizzled cysteinerich domains. Nature
  17. (2003). E: Differential regulation of midbrain dopaminergic neuron development by
  18. (2006). E: Dynamic temporal and cell type-specific expression of Wnt signaling components in the developing midbrain. Exp Cell Res
  19. (2009). E: Emerging role of Wnts in the adult nervous system. Nat Rev Neurosci
  20. (2004). E: GSK-3β inhibition/β-catenin stabilization in ventral midbrain precursors increases differentiation into dopamine neurons.
  21. (2009). E: Parkin protects dopaminergic neurons from excessive Wnt/β-catenin signalling. Biochem Biophys Rws Commun
  22. (2006). E: Ventral midbrain glia express region-specific transcription factors and regulate dopaminergic neurogenesis through Wnt-5a secretion. Mol Cell Neurosci
  23. (2004). EA: Members of the Wnt, Fz, and Frp gene families expressed in postnatal mouse cerebral cortex.
  24. (2007). et al: Genome wide atlas of gene expression in the adult mouse brain. Nature
  25. (2009). Expression of Wnt receptors in adult spiral ganglion neurons: frizzled 9 localization at growth cones of regenerating neurites. Neuroscience
  26. (2005). FH: Wnt signaling regulates adult hippocampal neurogenesis. Nature
  27. (1997). Fluoro-Jade: a novel fluorochrome for the sensitive and relialable histochemical localization of neuronal degeneration. Brain Res
  28. (2010). Gene expression profiling reveals molecular pathways associated with sporadic Parkinson’s disease. Brain Research
  29. (2006). Genetic networks controlling the development of midbrain dopaminergic neurons.
  30. (2010). Glia as a turning point in the therapeutic strategy of Parkinson’s disease.
  31. (2004). Glucocorticoid receptor deficiency increases vulnerability of the nigrostriatal dopaminergic system: critical role of glial nitric oxide.
  32. (2000). Glutathione metabolism in brain. Metabolic interaction between astrocytes and neurons in the defense against reactive oxygen species.
  33. (2004). Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxy dopamineinduced neuronal death. Faseb J
  34. (2006). Greenamyre JT: Intersecting pathways to neurodegeneration in Parkinson’s disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis
  35. (2005). Hagstrom JE: Delivery of small interfering RNA to mammalian cells in culture by using cationic lipid/polymer-based transfection reagents. Methods Enzymol
  36. (2001). He X: Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6. Curr Biol
  37. (2003). Hong JS: Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson’s disease.
  38. (2008). Hong JS: Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol
  39. (2009). Hunot S: Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol
  40. (1995). Idiopathic and 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism. In Neuroglia. Volume Chapter 65. Edited by: Kettenmann H, Ransom BR.
  41. (2010). Inestrosa NC: Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer’s disease. Mol Psychiatry
  42. (2003). Inestrosa NC: Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol Psychiatr
  43. (2008). Inestrosa NC: Frizzled-1 is involved in the neuroprotective effect of Wnt3a against Abeta oligomers.
  44. (2009). Inestrosa NC: Role of the Wnt receptor Frizzled-I in presynaptic differentiation and function. Neural Develop
  45. (2008). Inestrosa NC: Wnt signaling in neuroprotection and stem cell differentiation. Progr Neurobiol
  46. (2008). Inestrosa NC: Wnt-7a modulates the synaptic vesicle cycle and synaptic transmission in hippocampal neurons.
  47. (2007). Inhibition of glycogen synthase kinase-3β protects dopaminergic neurons from MPTP toxicity. Neuropharmacology
  48. (2009). Interruption of β-catenin signaling reduces neurogenesis in Alzheimer’s disease.
  49. (2009). Involment of cytosolic and mitochondrial GSK-3beta in mitochondrial dysfunction and neuronal cell death of MPTP/MPP +- treated neurons. Plos One
  50. Jho EH: Downregulation of Wnt/β-catenin signalling causes degeneration of hippocampal neurons in vivo.
  51. (2001). JM: Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson’s disease. Prog in Neurobiol
  52. (2001). Jope RS: The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol
  53. (2007). JZ: Phosphorylation of tau antagonizes apoptosis by stabilizing β-catenin, a mechanism involved in Alzheimers’s degeneration. Proc Natl Acad Sci USA
  54. (2007). LP: A regulatory circuit mediating convergence between Nurr1 transcriptional regulation and Wnt signalling. Mol Cell Biol
  55. (2008). McGeer EG: Glial reactions in Parkinson’s disease. Mov Disord
  56. (2005). Morale MC: Hormones are key actors in gene × environment interactions programming the vulnerability to Parkinson’sd i s e a s e : Glia as a common final pathway. Ann NY Acad Sci
  57. (2009). Mutations in the LRRK2 Roc-COR tandem domain link Parkinson’s disease to Wnt signalling pathway. Hum Mol Genet
  58. Neurodegeneration and prospects for neuroprotection and rescue in Parkinson’s disease. Annal Neurology 2003, 53:Suppl 3.
  59. (2006). Nusse R: Purified Wnt5a protein activates or inhibits betacatenin-TCF signaling depending on receptor context. PLoS Biol
  60. (2006). Nusse R: Wnt signaling: Multiple pathways, multiple receptors, and multiple transcription factors.
  61. (2009). NW: Characterization of a novel NR4A2 mutation in Parkinson’s disease. Neurosci Lett
  62. (2006). NW: Expanding insights of mitochondrial dysfunction in Parkinson’s disease. Nat Rev Neurosci
  63. (2002). OA: Wnt signalling protects 3T3-L1 preadipocytes from apoptosis through induction of insulin-like growth factors.
  64. (2008). Olanow CW: Differential modulation of Akt/Glycogen synthase kinase-3beta pathway regulates apoptotic and cytoprotective signalling responses.
  65. (2003). Olanow CW: Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinon’s disease. Ann Neurol
  66. (2005). Oxidative stress and inflammation in Parkinson’s disease: is there a causal link? Exp Neurol
  67. (2004). Parkinson’s divergent causes, convergent mechanisms. Science
  68. (1997). Paxinos G: The mouse brain in stereotaxic coordinates.
  69. (2005). PC: WNTs in the vertebrate nervous system: From patterning to neuronal connectivity. Nat Rev Neurosci
  70. (2005). PR: GSK3B polymorphism alter transcription and splicing in Parkinson’s disease. Ann Neurol
  71. (2007). Przedborski S: Protocol for the MPTP model of Parkinson’s disease. Nature Protocols
  72. (2011). Reactive astrocytes and Wnt/β-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. Neurobiol Dis
  73. (2000). Reichardt LF: Roles of Wnt proteins in neural development and maintenance. Curr Opin Neurobiol
  74. (2008). RNA interference of LRRK2-microarray expression analysis of a Parkinson’s disease key player. Neurogenetics
  75. (2009). Role of Dikkopf-1 (Dkk1), an antagonist of the Wnt-β-catenin signaling pathway, in estrogen-induced neuroprotection and attenuation of Tau phophorylation.
  76. (1976). RT: Interaction of Wnt and a inositol signalling. Nature
  77. (1999). RT: Protein kinase Cis differentially stimulated by Wnt and Frizzled homologs in a G-protein -dependent manner. Curr Biol
  78. (2006). RT: The ups and downs of Wnt signalling in prevalent neurological disorders. Oncogene
  79. (2007). Standaert DG: Effects of gender on nigral gene expression and parkinson’s disease. Neurobiol Dis
  80. (2008). Sun F-Y: β-catenin siRNA inhibits ischemiainduced striatal neurogenesis in adult rat brain following a transient middle cerebral artery occlusion. Neurosci Lett
  81. (2004). SW: Pro-regenerative properties of cytokine-activated astrocytes.
  82. (2008). SY: The Wnt signalling pathway: aging gracefully as a protectionist? Pharmacol Ther
  83. (1991). The neurotrophic effects of fibroblast growth factors on dopaminergic neurons in vitro are mediated by mesencephalic glia.
  84. (2008). The role of Wnt signalling in neuronal dysfunction in Alzheimer’s disease. Mol Neurodegen
  85. (2010). Vinters HB: Astrocytes: biology and pathology. Act Neuropatology
  86. (2005). WJ: Glia-Neuron Crosstalk in Neuroinflammation, Neurodegeneration and Neuroprotection. Brain Res Review S Issue
  87. (2008). Wnt and beyond Wnt: Multiple mechanisms control the transcriptional property of β-catenin. Cellular Signalling
  88. (2007). Wnt signalling promotes regeneration in the retina of adult mammals. Jo f Neurosci
  89. (2004). Wnt/beta-catenin and estrogen signaling converge in vivo.